Mega Genomics

Mega Genomics P/B

The P/B (Price-to-Book Ratio) of Mega Genomics (6667.HK) as of Oct 16, 2026 is 1.89. In the previous year, P/B (Price-to-Book Ratio) was 1.87 — a change of 0.61% (higher).

P/B

1.89

YoY

0.61%

Last updated:

P/B (Price-to-Book Ratio) of Mega Genomics is 2025 1.89 . P/B (Price-to-Book Ratio) of Mega Genomics was 2024 1.87 . It decreases by 0.61% higher compared to the previous year.

The Mega Genomics P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2019
-497.30 CNY
Jan 1, 2020
7.62 CNY
Jan 1, 2021
1.66 CNY
Jan 1, 2022
1.86 CNY
Jan 1, 2023
2.08 CNY
Jan 1, 2024
1.87 CNY
Jan 1, 2025
1.89 CNY
The Mega Genomics P/B history
YEARP/BYoY
1.89+0.61%
1.87-10.07%
2.08+11.80%
1.86+12.38%
1.66-78.23%
7.62-101.53%
-497.30—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Mega Genomics Stock analysis

What does Mega Genomics do? Mega Genomics Ltd, listed on the Hong Kong Stock Exchange under ticker 6667.HK with ISIN KYG5960G1047, is a health care company headquartered in Beijing, China. The company, which went public on June 22, 2022, employs 267 full-time staff. Mega Genomics operates as a genetic testing platform, offering consumer genetic testing and cancer screening services. Its business is structured into three segments. The Consumer Genetic Testing Services segment provides tests related to nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, pharmacogenetic testing, and infectious disease testing. The Cancer Screening Services segment offers specific tests including the Septin9 colorectal cancer screening test, Syndecan-2 (SDC2) colorectal cancer screening test, and the ring finger protein 180 (RNF180)/Septin9 gastric cancer screening test. The Other Services segment delivers genetic research and analysis services to third-party research institutions. The company's website is https://www.megagenomics.cn/. Mega Genomics focuses on providing genetic testing solutions for both consumer and clinical applications, with an emphasis on cancer-related screening and personalized health assessments. The company's operations are based in Beijing, reflecting its position within China's growing health care sector. As a publicly traded entity, Mega Genomics is subject to the regulatory requirements of the Hong Kong Stock Exchange. Mega Genomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mega Genomics stock

P/B (Price-to-Book Ratio) of Mega Genomics is 1.89 in 2025.

P/B (Price-to-Book Ratio) of Mega Genomics changed from 1.87 to 1.89, representing a 0.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Mega Genomics since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Mega Genomics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Mega Genomics

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Mega Genomics